Key facts
- This page summarizes Yuval Cabilly's Form 3 filing for Ayala Pharmaceuticals, Inc..
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Nov 2023, 16:01.
Yuval Cabilly - 18 Oct 2023 Form 3 Insider Report for Ayala Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 18 Oct 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Roy Golan, as attorney-in-fact for the Reporting Person
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Yuval Cabilly filed Form 3 for Ayala Pharmaceuticals, Inc. on 08 Nov 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 621,253
- Date
- 18 Oct 2023
- Ownership
- See footnote
- Footnotes
- F1, F4
ADXS
holding
Common Stock, par value $0.001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 677,386
- Date
- 18 Oct 2023
- Ownership
- See footnote
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The reported shares are held of record by Israel Biotech Fund I, L.P. ("IBF 1"). These shares were received by IBF 1 as a result of the merger, on or about January 19, 2023, of Old Ayala, Inc. (f/k/a Ayala Pharmaceuticals, Inc.) ("Old Ayala") with a wholly-owned subsidiary of the Issuer (f/k/a Advaxis, Inc.), pursuant to an Agreement and Plan of Merger (the "Advaxis Merger Agreement"), dated October 18, 2022, by and among the Issuer, Old Ayala and Doe Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer.
Footnote F2
The reported shares are held of record by IBF 1 and Israel Biotech Fund II, L.P. ("IBF 2"). These shares were received by IBF 1 and IBF 2 as a result of the merger, on October 18, 2023, of a wholly-owned subsidiary of the Issuer, Advaxis Israel Ltd. ("Merger Sub"), and Biosight, Ltd., a company organized under the laws of the State of Israel ("Biosight"), pursuant to an Agreement and Plan of Merger (the " Merger Agreement"), dated July 26, 2023, by and among the Issuer, Merger Sub and Biosight.
Footnote F3
Pursuant to the terms of the Merger Agreement, the shareholders of Biosight received 1.82285 shares of the common stock of the Issuer for each share of Biosight held by them immediately prior to the Closing Date.
Footnote F4
Israel Biotech Fund GP Partners, L.P. ("IBF I GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 1 and IBF 2. I.B.F Management Ltd. ("IBF Management"), an Israeli private company, is the management company of IBF I GP. By virtue of such relationships, IBF 1 GP and IBF Management may be deemed to have shared voting and investment power with respect to the shares held of record by IBF 1. Each of IBF 1 GP and IBF Management disclaims beneficial ownership of the shares held by IBF 1 and IBF 2, except to the extent of their pecuniary interest therein, if any. The reporting person disclaims beneficial ownership of the shares held by IBF 1 and IBF 2, except to the extent of his pecuniary interest therein, if any.